Generex Biotechnology Corporation
GNBT · OTC
4/30/2021 | 1/31/2021 | 10/31/2020 | 7/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -84.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | -218.9% | – | 73.6% | 71.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -30,746.6% | – | -15,958.6% | -900.6% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 44,566.3% | – | -291.7% | -2,153.8% |
| EPS | 0.081 | -0.22 | -0.11 | -0.15 |
| % Growth | 136.6% | -100% | 26.7% | – |
| EPS Diluted | 0.066 | -0.22 | -0.11 | -0.15 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 47,438.5% | – | -10,959.1% | -1,697.2% |